Abstract
Clinical trials have largely been unable to significantly reduce the mortality of alcoholic liver disease (ALD) beyond that achieved by placebo and alcohol withdrawal when the liver disease has progressed to the stages of alcoholic hepatitis or cirrhosis. This discouraging treatment outcome has reduced the frequency of clinical trials to treat ALD compared to the ongoing numbers of clinical trials to treat other chronic liver diseases such as hepatitis C (HCV), hepatitis B (HBV), and primary biliary cirrhosis [1]. This is despite the fact that the age-adjusted death rate (per 100,000) of ALD is 25 times higher than for primary biliary cirrhosis, 10.5 times higher than HBV, and 2.7 times higher than HCV [1].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
